Therapeutic Asset Ratings

18,140 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Adriamycin Glioblastoma	Université de Sherbrooke	P2	B (63)
Adriamycin Wilms Tumor	Children's National Research Institute	P2	B (63)
Alisertib Breast Cancer	Puma Biotechnology, Inc.	P2	B (63)
Azacitidine Myeloproliferative Neoplasm	Prelude Therapeutics	P2	B (63)
Bendamustine MALT Lymphoma	UNC Lineberger Comprehensive Cancer Center	P2	B (63)
Bendamustine Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	UNC Lineberger Comprehensive Cancer Center	P2	B (63)
Bendamustine Waldenstrom Macroglobulinemia	Brown University	P2	B (63)
Bexicaserin Lennox-Gastaut Syndrome	Longboard Pharmaceuticals	P2	B (63)
Bortezomib Breast Cancer	Sun Yat-sen University	P2	B (63)
Busulfanum Acute Undifferentiated Leukemia	Ossium Health, Inc.	P2	B (63)
Busulfanum Lymphoblastic Lymphoma	Masonic Cancer Center, University of Minnesota	P2	B (63)
Camustine HIV Infectious Disease	Fred Hutchinson Cancer Center	P2	B (63)
Capecitabine Glioblastoma	Northwell Health	P2	B (63)
Capecitabine Exocrine Pancreatic Carcinoma	Zhejiang University	P2	B (63)
Carboplatin Malignant Pleural Mesothelioma	AstraZeneca	P2	B (63)
Carboplatin Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	P2	B (63)
Carboplatin Anaplastic Oligodendroglioma	Oliver Jonas	P2	B (63)
Carboplatin Astrocytic Tumor	Oliver Jonas	P2	B (63)
Carboplatin Hereditary Breast Ovarian Cancer Syndrome	VA Office of Research and Development	P2	B (63)
Carboplatin Bladder Transitional Cell Carcinoma	Jonsson Comprehensive Cancer Center	P2	B (63)
Carboplatin Hypogonadism	University of Washington	P2	B (63)
Carboplatin Minimally Invasive Lung Adenocarcinoma	NRG Oncology	P2	B (63)
Carboplatin Plasma Cell Myeloma	Andrew Hantel, MD	P2	B (63)
Carboplatin Prostate Small Cell Carcinoma	M.D. Anderson Cancer Center	P2	B (63)
Carboplatin Lymphoblastic Lymphoma	New York Medical College	P2	B (63)

Showing 2901 to 2925 of 18,140 assets

PreviousPage 117 of 726Next